Clinical Trial Detail

NCT ID NCT03023904
Title Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

non-small cell lung carcinoma

Therapies

Nivolumab

Age Groups: senior adult

Additional content available in CKB BOOST